ARCHIVES

Five-Year Course of Tamoxifen Remains Standard Treatment In HR+ Breast Cancer

This article is from The Cancer Letter archive.

Vol. 25 No. 7 | July 26, 2002

Download PDF Visit The Full Archive

Related Articles

NIDA Supports Phase III Trial of Anti-Tobacco Vaccine

November 6, 2009

Group Chairs: Research In “Crisis” ASCO Says NCTN Budgets Cut By 40 Percent, Warns of “Dangerous Disruption of Cancer Care”

April 4, 2014

NCI Director To Decide Fate Of P-4 After NCAB Meeting In June.

April 20, 2007

Device Maker Threatens Legal Action Against Doctor Who Launched Campaign to End Power Morcellation

September 5, 2014

Komen Under Pressure: Charity Faces Money Woes, Attacks from Right

October 26, 2012

NCI to Support Research and Development Of Image Guided Therapy for Prostate Cancer

July 16, 1999